ECOPLAST
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture PCR Pro Instrument in India
Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.
Co-Diagnostics Inc. announced that its joint venture, CoSara Diagnostics Pvt. Ltd. (CoSara), has received a license from the Central Drugs Standard Control Organization (CDSCO) to manufacture the CoSara PCR Pro™ real-time PCR point-of-care instrument at its facility in Ranoli, India. The CDSCO license, issued on Form MD-5, authorizes the manufacturing and sale or distribution of the CoSara-branded Class A medical device instrument. This represents the final instrument license required by CDSCO before commercialization can begin. CoSara PCR test kits to be used with the instrument, such as those for Mycobacterium tuberculosis (MTB) and human papillomavirus (HPV), require separate regulatory clearance and are not yet available for sale.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA80385) on February 05, 2026, and is solely responsible for the information contained therein.
CoSara, assoziiertes Unternehmen von Co-Diagnostics Inc., erhält ISO 13485-Zertifizierung für PCR-Plattform
Das assoziierte Unternehmen von Co-Diagnostics Inc., CoSara Diagnostics Pvt. Ltd., hat die ISO 13485:2016-Zertifizierung für sein Qualitätsmanagementsystem und die Produktionsstätte in Vadodara, Indien, erhalten. Diese Zertifizierung gilt als wichtiger Schritt für die regulatorische Zulassung und die künftige Vermarktung einer neuen PCR-Plattform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.
Das assoziierte Unternehmen von Co-Diagnostics Inc., CoSara Diagnostics Pvt. Ltd., hat die ISO 13485:2016-Zertifizierung für sein Qualitätsmanagementsystem und die Produktionsstätte in Vadodara, Indien, erhalten. Diese Zertifizierung gilt als wichtiger Schritt für die regulatorische Zulassung und die künftige Vermarktung einer neuen PCR-Plattform.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.
Ecoplast To Consider Raising Of Fund
Dec 11 (Reuters) - Ecoplast Ltd ECOP.BO:
ECOPLAST LTD - TO CONSIDER RAISING OF FUND
Source text: ID:nBSE4cF3x6
Further company coverage: ECOP.BO
(([email protected];))
Dec 11 (Reuters) - Ecoplast Ltd ECOP.BO:
ECOPLAST LTD - TO CONSIDER RAISING OF FUND
Source text: ID:nBSE4cF3x6
Further company coverage: ECOP.BO
(([email protected];))
Ecoplast Dividend Of 3 Rupees Per Share
May 22 (Reuters) - Ecoplast Ltd ECOP.BO:
ECOPLAST LTD - DIVIDEND OF 3 RUPEES PER SHARE
Source text for Eikon: ID:nBSE7cw0fs
Further company coverage: ECOP.BO
(([email protected];))
May 22 (Reuters) - Ecoplast Ltd ECOP.BO:
ECOPLAST LTD - DIVIDEND OF 3 RUPEES PER SHARE
Source text for Eikon: ID:nBSE7cw0fs
Further company coverage: ECOP.BO
(([email protected];))
Ecoplast Says Vaibhav Kumar Totla Resigns As CFO
Nov 3 (Reuters) - Ecoplast Ltd ECOP.BO:
VAIBHAV KUMAR TOTLA RESIGNS AS CFO
NAMES SETU RUSHI PARIKH AS CFO
Source text for Eikon: ID:nBSE1T2VxP
Further company coverage: ECOP.BO
(([email protected];))
Nov 3 (Reuters) - Ecoplast Ltd ECOP.BO:
VAIBHAV KUMAR TOTLA RESIGNS AS CFO
NAMES SETU RUSHI PARIKH AS CFO
Source text for Eikon: ID:nBSE1T2VxP
Further company coverage: ECOP.BO
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Ecoplast do?
Ecoplast Limited is a company based in Abrama-Valsad, engaged in manufacturing and selling Co extruded Plastic Film for packaging and industrial applications. It serves both domestic and international markets and holds certifications like ISO 9001, ISO 14001, and ISO 22000.
Who are the competitors of Ecoplast?
Ecoplast major competitors are Hindustan Adhesives, Aeron Composite, National PlasticTech, Harshdeep Hortico, Apt Packaging, BD Industries (Pune), KV Toys India. Market Cap of Ecoplast is ₹148 Crs. While the median market cap of its peers are ₹150 Crs.
Is Ecoplast financially stable compared to its competitors?
Ecoplast seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Ecoplast pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Ecoplast latest dividend payout ratio is 9.81% and 3yr average dividend payout ratio is 9.97%
How has Ecoplast allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Ecoplast balance sheet?
Balance sheet of Ecoplast is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Ecoplast improving?
No, profit is decreasing. The profit of Ecoplast is ₹7.51 Crs for TTM, ₹8.46 Crs for Mar 2025 and ₹9.17 Crs for Mar 2024.
Is the debt of Ecoplast increasing or decreasing?
Yes, The net debt of Ecoplast is increasing. Latest net debt of Ecoplast is -₹7.27 Crs as of Sep-25. This is greater than Mar-25 when it was -₹19.5 Crs.
Is Ecoplast stock expensive?
Ecoplast is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Ecoplast is 19.91, while 3 year average PE is 14.35. Also latest EV/EBITDA of Ecoplast is 11.9 while 3yr average is 20.72.
Has the share price of Ecoplast grown faster than its competition?
Ecoplast has given lower returns compared to its competitors. Ecoplast has grown at ~-26.26% over the last 1yrs while peers have grown at a median rate of -11.36%
Is the promoter bullish about Ecoplast?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Ecoplast is 64.84% and last quarter promoter holding is 64.84%.
Are mutual funds buying/selling Ecoplast?
There is Insufficient data to gauge this.
